VVRA-TM 009

VVRA-TM 009 is an investigational sublingual drug candidate being developed by Vivera Biosciences for the treatment of Childhood-Onset Fluency Disorder (stuttering). The drug utilizes Vivera's proprietary, patented TABMELT sublingual drug delivery system, which allows the medication to dissolve under the tongue. This sublingual route is designed to bypass the gastrointestinal tract and first-pass liver metabolism, potentially leading to rapid absorption and more consistent bioavailability compared to traditional oral administration. VVRA-TM 009 is part of Vivera's neurosciences pipeline aimed at addressing the underlying neurological basis of speech disfluencies.